Herpes zoster and vaccination: A clinical review

American Journal of Health-System Pharmacy

Volumn 67, Issue 9, 2010, Pages 724-727

  Adams, Erin N ^a   Sarah, Parnapy ^a   Philip, Bautista ^b  

^a SHENANDOAH UNIVERSITY   (United States)

^b The Inova Fairfax Transplant Center   (United States)

Author keywords

Epidemiology; Herpes zoster vaccines; Immunization; Neuralgia; Pharmacoeconomics; Quality of life; Toxicity; Vaccines

Indexed keywords

ACICLOVIR; ANTICONVULSIVE AGENT; CAPSAICIN; CORTICOSTEROID; FAMCICLOVIR; NONSTEROID ANTIINFLAMMATORY AGENT; TRICYCLIC ANTIDEPRESSANT AGENT; VALACICLOVIR; VARICELLA ZOSTER VACCINE;

CHRONIC PAIN; CLINICAL ASSESSMENT; CLINICAL FEATURE; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; HEALTH CARE COST; HERPES ZOSTER; HUMAN; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; INSURANCE; MEDICAID; MEDICARE; MORBIDITY; OUTCOME ASSESSMENT; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; TREATMENT OUTCOME; VACCINATION; VARICELLA ZOSTER VIRUS; COST BENEFIT ANALYSIS; ECONOMICS; IMMUNOLOGY; MIDDLE AGED; NEURALGIA; PATHOPHYSIOLOGY; VIROLOGY;

COST-BENEFIT ANALYSIS; HERPES ZOSTER; HERPES ZOSTER VACCINE; HUMANS; MIDDLE AGED; NEURALGIA; QUALITY OF LIFE;

EID: 77954349776     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp090118     Document Type: Review

References (34)

1. Harpaz R, Ortega-Sanchez IR, Seward JF. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2008; 57:1-30.
2. Johnson RW, Wasner G, Saddier P et al. Herpes zoster and postherpetic neuralgia: optimizing management in the elderly patient. Drugs Aging. 2008; 25:991-1006.
3. Stankus SJ, Dlugopolski M, Packer D. Management of herpes zoster (shingles) and postherpetic neuralgia. Am Fam Physician. 2000; 61:2437-44,2447-8.
4. Arvin A. Aging, immunity and the varicella-zoster virus. N Engl J Med. 2005; 352:2266-7.
5. Hicks LD, Cook-Norris RH, Mendoza N et al. Family history as a risk factor for herpes zoster: a case-control study. Arch Dermatol. 2008; 144:603-8. (Pubitemid 351724420)
6. Merck & Co. Zoster incidence. www.merckvaccines.com/diseaseInfo-f rmst.html?/diseases/zoster/zos-incidence (accessed 2009 May 4).
7. Gnann JW, Whilet RJ. Herpes zoster. N Engl J Med. 2002; 347:340-6.
8. Mayo Clinic. Shingles. www.mayoclinic. com/health/shingles/DS00098 (accessed 2009 May 3).
9. Gilderman LI, Lawless JF, Nolen TM. A double-blind, randomized, controlled, multicenter safety and immunogenicity study of a refrigerator-stable formulation of Zostavax. Clin Vaccine Immunol. 2008; 15:314-9.
10. Centers for Disease Control and Prevention. Shingles disease - questions and answers (herpes zoster). www.cdc.gov/ vaccines/vpd-vac/shingles/dis-faqs.htm (accessed 2009 Apr 29).
11. Weaver BA. The burden of herpes zoster and postherpetic neuralgia in the United States. J Am Osteopath Assoc. 2007; 107(suppl 1):S2-7.
12. Johnson RW. Consequences and management of pain in herpes zoster. J Infect Dis. 2002; 186(suppl 1):S83-90.
13. Dubinsky RM, Kabbani H, El-Chami Z et al. Practice parameter: treatment of post-herpetic neuralgia: an evidenced-based report of the quality standards subcommittee of the American Academy of Neurology. Neurology. 2004; 63:959-65.
14. Mayo Clinic. Postherpetic neuralgia. www.mayoclinic.com/health/ postherpetic-neuralgia/DS00277 (accessed 2009 Jan 20).
15. Katz J, Cooper EM, Walther RR et al. Acute pain in herpes zoster and its impact on health-related quality of life. Clin Infect Dis. 2004; 39:342-8. (Pubitemid 39050481)
16. Christo PJ, Hobelmann G, Maine DN. Post-herpetic neuralgia in older adults: evidence-based approaches to clinical management. Drugs Aging. 2007; 24:1-19.
17. Dworkin RH, Johnson RW, Breuer J et al. Recommendations for the management of herpes zoster. Clin Infect Dis. 2007; 44(suppl 1):S1-26.
18. Food and Drug Administration. Zostavax (herpes zoster vaccine) questions and answers. www.fda.gov/BiologicsBlood Vaccines/Vaccines/Questionsabout Vaccines/UCM070418 (accessed 2010 Jan 28).
19. Zostavax (zoster vaccine live) prescribing information. Whitehouse Station, NJ: Merck & Co.; 2008 Dec.
20. Levin MJ, Oxman MN, Zhang JH et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J Infect Dis. 2008; 197:825-35.
21. Kimberlin DW, Whitley RJ. Varicellazoster vaccine for the prevention of herpes zoster. N Engl J Med. 2007; 356:1338-43.
22. Oxman MN, Levin MJ, Johnson GR et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005; 352:2271-84.
23. Gnann JW Jr. Vaccination to prevent herpes zoster in older adults. J Pain. 2008; 9(suppl 1):S31-6.
24. Centers for Disease Control and Prevention. CDC vaccine price list. www.cdc.gov/ vaccines/programs/vfc/cdc-vac-pricelist. htm (accessed 2009 Feb 10).
25. Centers for Medicare and Medicaid Services. Medicare preventative services quick reference information: Medicare Part B immunization billing. www.cms.hhs.gov/mlnproduct s / downloads/qr-immun-bill.pdf (accessed 2009 Feb 1).
26. Merck & Co. Pathways to reimbursement for Zostavax. www.merckvaccines.com/ vaccines/zostavax/pathwaysTo Reimbursement.pdf (accessed 2010 Jan 26).
27. Moore KJ. Billing for Medicare Part D vaccines. Fam Pract Manag. 2007; 14:33-4.
28. Centers for Disease Control and Prevention. Herpes zoster vaccine Q&A (shingles). www.cdc.gov/vaccines/vpd-vac/ shingles/vac-faqs.htm (accessed 2009 Feb 1).
29. Dworkin RH, White R, O'Connor AB et al. Health care expenditure burden of persisting herpes zoster pain. Pain Med. 2008; 9:348-53.
30. Hornberger J, Robertus K. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Ann Intern Med. 2006; 145:317-25. (Pubitemid 46768588)
31. Pellissier JM, Brisson M, Levin MJ. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Vaccine. 2007; 25:8326-37.
32. Rothberg MB, Virapongse A, Smith KJ. Cost-effectiveness of a vaccine to prevent herpes zoster and post-herpetic neuralgia in older adults. Clin Infect Dis. 2007; 44:1280-8.
33. Merck & Co. Zostavax prescribing information. Whitehouse Station, NJ: 2009 Dec.
34. MacIntyre C, Egerton T, McCaughey M et al. Concomitant administration of zoster and pneumococcal vaccines in adults ≥ 60 years old. Paper presented at 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy/46th Annual Meeting of Infectious Diseases Society of America. Washington, DC; 2008 Oct.